# A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

> **NCT01225302** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 12 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Linifanib
- **DRUG:** Linifanib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01225302
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225302, "A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01225302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*